Gene Therapy: Future or Flop

Pediatric Clinics of North America

Volumn 53, Issue 4, 2006, Pages 621-638

  Park, Frank ^a   Gow, Kenneth W ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; CD34 ANTIGEN; COMPLEMENTARY RNA; CYTOSINE DEAMINASE; GANCICLOVIR; GEMCITABINE; LENTIVIRUS VECTOR; NUCLEIC ACID; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE;

ADENOSINE DEAMINASE DEFICIENCY; BETA THALASSEMIA; CHILDHOOD DISEASE; CLINICAL TRIAL; DENDRITIC CELL; ENZYME DEFICIENCY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MUTAGENESIS; NONHUMAN; REVIEW; RNA INTERFERENCE; SICKLE CELL ANEMIA; SUICIDE GENE THERAPY; TECHNOLOGY; TRANS SPLICING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INHIBITION;

FEMALE; FETAL DISEASES; FORECASTING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; NUCLEIC ACIDS; PEDIATRICS; PREGNANCY; VIRUSES;

EID: 33746253818     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2006.05.003     Document Type: Review

References (94)

1. Feigin R.D. Prospects for the future of child health through research. JAMA 294 (2005) 1373-1379
2. Rimoin D.L., and Hirschhorn K. A history of medical genetics in pediatrics. Pediatr Res 56 (2004) 150-159
3. Wolff J.A., and Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 54 (2005) 3-20
4. Xu L., Yee J.K., Wolff J.A., et al. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 171 (1989) 331-341
5. Blaese R.M., Culver K.W., Miller A.D., et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270 (1995) 475-480
6. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10 (1990) 4239-4242
7. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
8. Baum C., von Kalle C., Staal F.J., et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9 (2004) 5-13
9. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003) 255-256
10. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
11. Kohn D.B., Sadelain M., Dunbar C., et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 8 (2003) 180-187
12. Naldini L., Blomer U., Gage F.H., et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93 (1996) 11382-11388
13. Naldini L., Blomer U., Gallay P., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
14. Park F., Ohashi K., Chiu W., et al. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 24 (2000) 49-52
15. Kumar M., Keller B., Makalou N., et al. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12 (2001) 1893-1905
16. Kang Y., Stein C.S., Heth J.A., et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol 76 (2002) 9378-9388
17. Park F. Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum Gene Ther 14 (2003) 1489-1494
18. Qian Z, Haessler M, Lemos JA, et al. Targeting vascular injury using hantavirus-pseudotyped lentiviral vectors. Mol Ther, in press.
19. Sinn P.L., Penisten A.K., Burnight E.R., et al. Gene transfer to respiratory epithelia with lentivirus pseudotyped with Jaagsiekte sheep retrovirus envelope glycoprotein. Hum Gene Ther 16 (2005) 479-488
20. Miyoshi H., Blomer U., Takahashi M., et al. Development of a self-inactivating lentivirus vector. J Virol 72 (1998) 8150-8157
21. De Palma M., Montini E., de Sio F.R., et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105 (2005) 2307-2315
22. Ohashi K., Park F., and Kay M.A. Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther 13 (2002) 653-663
23. Park F., Ohashi K., and Kay M.A. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 96 (2000) 1173-1176
24. Tsui L.V., Kelly M., Zayek N., et al. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 20 (2002) 53-57
25. Park F., Ohashi K., and Kay M.A. The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. Mol Ther 8 (2003) 314-323
26. VandenDriessche T., Thorrez L., Naldini L., et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100 (2002) 813-822
27. Case S.S., Price M.A., Jordan C.T., et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96 (1999) 2988-2993
28. Mostoslavsky G., Kotton D.N., Fabian A.J., et al. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther 11 (2005) 932-940
29. Humeau L.M., Binder G.K., Lu X., et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV + infected patients grouped according to CD4 count and viral load. Mol Ther 9 (2004) 902-913
30. Manilla P., Rebello T., Afable C., et al. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16 (2005) 17-25
31. Bank A., Dorazio R., and Leboulch P.A. Phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann N Y Acad Sci 1054 (2005) 308-316
32. Bergelson J.M., Krithivas A., Celi L., et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 72 (1998) 415-419
33. Lozier J.N., Csako G., Mondoro T.H., et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 13 (2002) 113-124
34. Lozier J.N., Metzger M.E., Donahue R.E., et al. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 94 (1999) 3968-3975
35. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80 (2003) 148-158
36. Delatte S.J., Hazen-Martin D.J., Re G.G., et al. Restoration of p53 function in anaplastic Wilms' tumor. J Pediatr Surg 36 (2001) 43-50
37. Borovjagin A.V., Krendelchtchikov A., Ramesh N., et al. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther 12 (2005) 475-486
38. Douglas J.T., Rogers B.E., Rosenfeld M.E., et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14 (1996) 1574-1578
39. Haviv Y.S., Blackwell J.L., Kanerva A., et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 62 (2002) 4273-4281
40. Ehrhardt A., and Kay M.A. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99 (2002) 3923-3930
41. Ehrhardt A., Xu H., Dillow A.M., et al. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102 (2003) 2403-2411
42. DelloRusso C., Scott J.M., Hartigan-O'Connor D., et al. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 99 (2002) 12979-12984
43. Miao C.H., Snyder R.O., Schowalter D.B., et al. The kinetics of rAAV integration in the liver. Nat Genet 19 (1998) 13-15
44. Snyder R.O., Miao C.H., Patijn G.A., et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16 (1997) 270-276
45. Nakai H., Yant S.R., Storm T.A., et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75 (2001) 6969-6976
46. Couto L.B. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors. Semin Thromb Hemost 30 (2004) 161-171
47. Miao C.H., Nakai H., Thompson A.R., et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 74 (2000) 3793-3803
48. Nakai H., Thomas C.E., Storm T.A., et al. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 76 (2002) 11343-11349
49. Kay M.A., Manno C.S., Ragni M.V., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24 (2000) 257-261
50. Manno C.S., Chew A.J., Hutchison S., et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003) 2963-2972
51. Kaiser J. Gene therapy. Side effects sideline hemophilia trial. Science 304 (2004) 1423-1425
52. Gao G., Lu Y., Calcedo R., et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13 (2006) 77-87
53. Gao G., Vandenberghe L.H., and Wilson J.M. New recombinant serotypes of AAV vectors. Curr Gene Ther 5 (2005) 285-297
54. Grimm D., Zhou S., Nakai H., et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102 (2003) 2412-2419
55. Nakai H., Fuess S., Storm T.A., et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 79 (2005) 214-224
56. Gao G.P., Alvira M.R., Wang L., et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99 (2002) 11854-11859
57. Shankar P., Manjunath N., and Lieberman J. The prospect of silencing disease using RNA interference. JAMA 293 (2005) 1367-1373
58. Sangkhathat S., Kusafuka T., Miao J., et al. In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol 28 (2006) 715-722
59. Damm-Welk C., Fuchs U., Wossmann W., et al. Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin Cancer Biol 13 (2003) 283-292
60. Bauer G., Selander D., Engel B., et al. Gene therapy for pediatric AIDS. Ann N Y Acad Sci 918 (2000) 318-329
61. Kohn D.B., Bauer G., Rice C.R., et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94 (1999) 368-371
62. Morris K.V., and Rossi J.J. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 13 6 (2006) 553-558
63. Sullenger B.A. Targeted genetic repair: an emerging approach to genetic therapy. J Clin Invest 112 (2003) 310-311
64. Yang Y., and Walsh C.E. Spliceosome-mediated RNA trans-splicing. Mol Ther 12 (2005) 1006-1012
65. Chao H., Mansfield S.G., Bartel R.C., et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 9 (2003) 1015-1019
66. Lai Y., Yue Y., Liu M., et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23 (2005) 1435-1439
67. Liu X., Luo M., Zhang L.N., et al. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 16 (2005) 1116-1123
68. Lipshutz G.S., Gruber C.A., Cao Y., et al. In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol Ther 3 (2001) 284-292
69. Lipshutz G.S., Sarkar R., Flebbe-Rehwaldt L., et al. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA 96 (1999) 13324-13329
70. Waddington S.N., Mitrophanous K.A., Ellard F.M., et al. Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Ther 10 (2003) 1234-1240
71. Waddington S.N., Nivsarkar M.S., Mistry A.R., et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 104 (2004) 2714-2721
72. Follenzi A., Battaglia M., Lombardo A., et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103 (2004) 3700-3709
73. American Academy of Pediatrics Committee on Genetics. Molecular genetic testing in pediatric practice: A subject review. Pediatrics 106 (2000) 1494-1497
74. Jooss K., Ertl H.C., and Wilson J.M. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 72 (1998) 2945-2954
75. Wang L., Cao O., Swalm B., et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 12 (2005) 1453-1464
76. Mingozzi F., Liu Y.L., Dobrzynski E., et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111 (2003) 1347-1356
77. Kay M.A., Holterman A.X., Meuse L., et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 11 (1995) 191-197
78. Halbert C.L., Standaert T.A., Wilson C.B., et al. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 72 (1998) 9795-9805
79. Feili-Hariri M., Dong X., Alber S.M., et al. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48 (1999) 2300-2308
80. Xiao B.G., Duan R.S., Link H., et al. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol 223 (2003) 63-69
81. Zhao P, Park F, Cui Y. Engineering hematopoietic stem cells to modulate immune response. In: LaRussa VF, editor. Stem cell: research tools and transplantation (methods in molecular biology). New Jersey: Humana Press; in press.
82. Seshidhar Reddy P., Ganesh S., Limbach M.P., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 311 (2003) 384-393
83. Franco L.M., Sun B., Yang X., et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12 (2005) 876-884
84. Liu Y.L., Mingozzi F., Rodriguez-Colon S.M., et al. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector. Hum Gene Ther 15 (2004) 783-792
85. Zaiss A.K., Son S., and Chang L.J. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 76 (2002) 7209-7219
86. Germano I.M., Fable J., Gultekin S.H., et al. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 65 (2003) 279-289
87. Wiewrodt R., Amin K., Kiefer M., et al. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 10 (2003) 353-364
88. Painter R.G., Lanson Jr. N.A., Jin Z., et al. Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis. Cancer Sci 96 (2005) 607-613
89. Boucher P.D., and Shewach D.S. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol Ther 12 (2005) 1064-1071
90. Ginsburg D.S., and Calos M.P. Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv Genet 54 (2005) 179-187
91. Bertoni C., Jarrahian S., Wheeler T.M., et al. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci USA 103 (2006) 419-424
92. Held P.K., Olivares E.C., Aguilar C.P., et al. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 11 (2005) 399-408
93. Olivares E.C., Hollis R.P., Chalberg T.W., et al. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol 20 (2002) 1124-1128
94. Tan W., Zhu K., Segal D.J., et al. Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol 78 (2004) 1301-1313